Trial profile showing the number of children assessed for stunting, screened, recruited to each intervention group and lost to follow-up.
malaria, anemia
ADVERSE EVENTS, EVENTS, MALARIA, ANEMIA
Loss to follow-up was defined as those not returning for the 12-week visit. LNS, lipid-based nutrient supplement.Eleven serious adverse events were reported among 10 (1.3%) children, 8 (1.3%) of whom received LNS while 2 (1.3%) did not. All were due to hospitalization with life-threatening conditions, mainly severe malaria and anemia. The events were deemed unrelated to the trial intervention and no children died.At inclusion, the median (interquartile range, IQR) age was 30 (23, 41) months, and the mean ± SD HAZ was −3.02 ± 0.74. The proportion still breastfed was 12.7% (95), 39% (86) among those below and 1.7% (9) among those above 2 years. More than half (59%) had consumed at least 1 animal-source food the previous day. The randomization resulted in baseline equivalence, except for currently breastfed, diverse diet, and positive malaria test (